Latest Insider Transactions at Rhythm Pharmaceuticals, Inc. (RYTM)
This section provides a real-time view of insider transactions for Rhythm Pharmaceuticals, Inc. (RYTM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of RHYTHM PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of RHYTHM PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2022
|
Hunter C Smith Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,547
-11.58%
|
$30,188
$4.08 P/Share
|
|
Jun 30
2022
|
Hunter C Smith Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+27.73%
|
-
|
|
Mar 29
2022
|
William T. Roberts Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,023
-40.92%
|
$11,253
$11.13 P/Share
|
|
Mar 29
2022
|
William T. Roberts Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
-
|
|
Feb 15
2022
|
Jennifer Chien EVP, Head of North America |
SELL
Open market or private sale
|
Direct |
722
-35.53%
|
$4,332
$6.1 P/Share
|
|
Feb 15
2022
|
Yann Mazabraud EVP, Head of International |
SELL
Open market or private sale
|
Direct |
934
-45.96%
|
$5,604
$6.1 P/Share
|
|
Feb 15
2022
|
Hunter C Smith Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
833
-2.03%
|
$4,998
$6.1 P/Share
|
|
Feb 15
2022
|
Joseph Shulman Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
557
-35.64%
|
$3,342
$6.1 P/Share
|
|
Feb 11
2022
|
Jennifer Chien EVP, Head of North America |
BUY
Exercise of conversion of derivative security
|
Direct |
2,032
+50.0%
|
-
|
|
Feb 11
2022
|
Yann Mazabraud EVP, Head of International |
BUY
Exercise of conversion of derivative security
|
Direct |
2,032
+50.0%
|
-
|
|
Feb 11
2022
|
Hunter C Smith Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+5.41%
|
-
|
|
Feb 11
2022
|
Joseph Shulman Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,563
+50.0%
|
-
|
|
Apr 21
2021
|
Hunter C Smith Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.45%
|
$30,000
$6.88 P/Share
|
|
Mar 30
2021
|
David P Meeker President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+8.24%
|
$200,000
$20.17 P/Share
|
|
Mar 15
2021
|
Todd Foley Director |
SELL
Open market or private sale
|
Indirect |
1,000,000
-52.38%
|
$25,000,000
$25.1 P/Share
|
|
Jan 19
2021
|
Hunter C Smith Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+10.62%
|
$24,000
$6.88 P/Share
|
|
Dec 03
2020
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
207,604
-1.15%
|
$6,020,516
$29.51 P/Share
|
|
Dec 02
2020
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
30,939
-0.34%
|
$990,048
$32.37 P/Share
|
|
Jul 02
2020
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
44,153
-0.85%
|
$971,366
$22.04 P/Share
|
|
Jul 01
2020
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
25,527
-0.49%
|
$536,067
$21.87 P/Share
|
|
Jun 30
2020
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
61,901
-1.17%
|
$1,361,822
$22.15 P/Share
|
|
Jun 29
2020
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
52,049
-0.98%
|
$1,145,078
$22.19 P/Share
|
|
Jun 26
2020
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
86,706
-1.6%
|
$1,994,238
$23.31 P/Share
|
|
Jun 25
2020
|
Ra Capital Management, L.P. |
SELL
Open market or private sale
|
Indirect |
11,568
-0.21%
|
$289,200
$25.05 P/Share
|
|
May 22
2018
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
19,580
-0.35%
|
$587,400
$30.67 P/Share
|
|
May 21
2018
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
62,500
-2.21%
|
$1,937,500
$31.01 P/Share
|
|
May 18
2018
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
69,136
-2.38%
|
$2,074,080
$30.77 P/Share
|
|
Oct 10
2017
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
355,000
+10.9%
|
$6,035,000
$17.0 P/Share
|
|
Oct 10
2017
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,546,295
+50.0%
|
-
|
|
Oct 10
2017
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
355,000
+27.48%
|
$6,035,000
$17.0 P/Share
|
|
Oct 10
2017
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
582,010
+50.0%
|
-
|
|
Oct 05
2017
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
885,000
+31.88%
|
$15,045,000
$17.0 P/Share
|
|
Oct 05
2017
|
Baker Bros. Advisors LP |
BUY
Conversion of derivative security
|
Indirect |
1,164,020
+50.0%
|
-
|